Rationale Upregulation of glucocorticoid receptor
INTRODUCTION
Patients with severe asthma respond poorly to available therapies, which results in high healthcare costs due to unscheduled healthcare visits, treatment of co-morbidities and work absence. 1 The cornerstone of asthma treatment is glucocorticoid therapy; however patients with severe asthma are relatively resistant to inhaled glucocorticoids, often resulting in a requirement for systemic steroids to maintain disease control. 2 Proposed molecular mechanisms for glucocorticoid resistance include abnormalities of glucocorticoid binding, 2e4 reduced glucocorticoid receptor nuclear translocation in response to steroids, 5 6 increased expression of pro-inflammatory transcription factors (eg, activator protein-1 and nuclear factor-kB) 7 8 and altered expression of co-repressor proteins (eg, histone deacetylases). 9 Two commonly proposed mechanisms for steroid resistance in severe asthma are increased expression of the dominant negative isoform of the glucocorticoid receptor, glucocorticoid receptor b (GRb), and reduced expression and activity of histone deacetylase 2 (HDAC2). 3 5 A recent study suggested the reduced HDAC2 in severe asthma may be regulated by GRb overexpression. 10 Existing data on GRb expression in severe asthma have been variable. GRb-immunoreactive peripheral blood mononuclear cells (PBMCs), CD3 T cells and bronchoalveolar lavage cells were increased in steroid-resistant asthma. 3 11 12 Furthermore, Sousa et al reported increased GRbpositive cells in steroid-resistant asthmatic tuberculin responses. 13 In the lungs of patients who have died from asthma increased GRb immunoreactivity has been reported, 14 and in the only published
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What is the key question?
< Increased glucocorticoid receptor b (GRb) with resultant reduction in histone deacetylase 2 (HDAC2) expression has been implicated in the pathogenesis of severe steroid-resistant asthma, but previous data are conflicting.
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bronchial biopsy study, GRb expression detected by immunohistochemistry was increased in the epithelium and submucosa of patients with severe asthma. 15 However, other studies in PBMCs in severe asthma have been negative. 16 17 Thus, it remains unclear if GRb is elevated in the airways of severe asthma (and other 'steroid resistant' conditions) and why there is such variability in the published literature.
Our aims were to examine GRb and GRa expression at transcript and protein levels in bronchial biopsies from a large series of patients with severe asthma, and to compare the findings with those for patients with mild to moderate asthma and healthy volunteers. We also studied HDAC1 and HDAC2 expression in matched biopsies.
METHODS Subjects
This study was performed in two UK centres, Queens University Belfast and University of Leicester. Patients with severe asthma were recruited from the Belfast City Hospital and Glenfield Hospital, Leicester Difficult Asthma Services, where systematic evaluation protocols ensure patients have well characterised severe asthma as defined by current American Thoracic Society guidelines. 18 All patients had persisting symptoms despite treatment at step 4 or 5 of the Global Initiative for Asthma (GINA) guidelines. 19 Patients with mild to moderate asthma and healthy volunteers were recruited from hospital clinics or by advertisement.
In total, 27 participants were recruited from Belfast (10 healthy volunteers (HV), 7 patients with mild to moderate asthma (MA) and 10 patients with severe asthma (SA)) and 56 participants from Leicester (12 HV, 23 MA and 21 SA) (table 1).
Bronchoscopy
Bronchoscopy was performed using standard techniques (see online supplement). Biopsies were either placed immediately in RNA preservative (RNAlater, Ambion, Austin, Texas, USA) and submitted for real-time PCR (qPCR) or placed into dry acetone containing protease inhibitors (iodoacetamide and phenylmethylsulfonyl fluoride) and fixed overnight at À208C for immunohistochemistry. Brushings were placed in Promocell medium containing penicillin/streptomycin and Primocin for cell culture (Promocell, Heidelberg, Germany).
Gene expression analysis
qPCR analysis was performed using RNA from homogenised bronchial biopsies (74 biopsies; 22 HV, 28 MA and 24 SA) using TaqManÒ Gene Expression Assays (Applied Biosystems, Foster City, California, USA). RNA purification and qPCR quality control are detailed in the online supplement. Relative expression levels were determined by the 2(-DeltaDelta C T ) method, as described in Applied Biosystems User Bulletin No. 2 (P/N 4303859). 20 
Bronchial biopsy immunohistochemistry and confocal microscopy
For immunohistochemistry, biopsy samples were processed and stained using local protocols. Fifty-five biopsies (17 HV, 21 MA and 17 SA) were processed for immunohistochemistry. Infiltration and embedding with JB4 resin was performed. 21 The immunohistochemical technique and confocal analysis are detailed in the online supplement.
Immunostained sections were evaluated by two independent assessors with consensus scoring for any conflicting results (scoring system given in the online supplement). Two polyclonal anti-GRb antibodies were compared, ab3581 (Abcam, Cambridge, UK) and PA3-514 (Affinity Bioreagents, Golden, CO, USA via Pierce Biotechnology, Rockford, IL, USA) along with anti-GRa (sc-1002), HDAC1 (sc-7872) and HDAC2 (sc-7899) (Insight Biotechnology, Wembley, UK).
Epithelial cell culture and western blotting
Bronchial epithelial brushings (Belfast cohort) were cultured (Promocell) and lysates (NE-PER lysis kit, Pierce Biotechnology, MSC, Dublin) used for western blot experiments (see online supplement). For clathrin identification blots, anti-clathrin antibody (ab2731, Abcam) was used. For immunoprecipitation, BEAS-2B cells (ATCC, Manassas, VA, USA) were also used following culture in supplemented Dulbecco's Modified Eagle's Medium (Gibco-Invitrogen Ltd, Paisley, UK).
Immunocytochemistry
Primary bronchial epithelial cells (PBECs) were grown onto collagen-coated Thermanox coverslips (catalogue no. 174950, Nalge Nunc International, Rochester, NY, USA), permeabilised and stained (see online supplement), and mounted on slides.
Immunoprecipitation
Immunoprecipitation was performed using IgA Magnetic Beads (Pierce Biotechnology, Rockford, IL, USA). PBECs and BEAS-2B cells were used. The method is detailed in the online supplement and the resultant blots were probed with anti-GRb and anticlathrin (ab2731, Abcam) antibodies. In addition, increasing amounts (250 ng, 500 ng, 1000 ng and 2500 mg) of recombinant clathrin was run on a gel and the blot probed with anti-GRb and anti-clathrin antibodies.
Proteomics
Protein identification was performed by the Proteomics Facility, University of Dundee, UK. Following immunoprecipitation, gels were stained with Coomassie blue and the higher molecular weight band cut out of the gel, digested with trypsin prior to analysis by one-dimensional nano-scale liquid chromatography tandem mass spectrometry (nLC-MS-MS) and protein identification performed with Mascot (www.matrixscience.com/).
Statistical analysis
The statistical package Prism (GraphPad Prism version 4.00 for Windows, GraphPad Software, San Diego, California, USA) was used to generate graphs and perform appropriate statistical analysis. Data are presented as median (IQR) unless otherwise stated. Between-group data were analysed using one-way analysis of variance (KruskaleWallis) with Dunn's post hoc test or Wilcoxon Signed Rank test as appropriate. A p value <0.05 was considered significant.
RESULTS

GRb, GRa, HDAC1 and HDAC2 mRNA expression
In the samples available for qPCR (n¼74), GRb mRNA was detectable in only 13 of the 74 (18%) participants (seven SAdfour of whom were on oral steroids, four with moderate persistent asthma on inhaled steroids, one with steroid-naive asthma and one HV) ( figure 1A ). There was a similar rate of detection in the SA group (p¼0.10, Fisher's exact test). Despite the use of different specific primer-probe sets for GRb, GRb mRNA was not detected in any of the other samples. Immunohistochemistry for GRb, GRa, HDAC1 and HDAC2 and relation to asthma severity in bronchial biopsies
Similar location and intensity of immunostaining for GRb was seen using both immunohistochemistry protocols (figure 2A). Identical staining was noted with both GRb antibodies (data not shown). The most striking observation was the intensity of immunostaining in contrast to low mRNA expression. GRb immunostaining was mainly localised to the epithelium with scant submucosal expression in glands, smooth muscle cells and inflammatory cells ( figure 2A,B) . Confocal microscopy revealed that epithelial immunostaining with GRb antibodies was predominantly cytoplasmic, though some cells did demonstrate nuclear staining ( figure 2D ).
There was no significant between-group difference in epithelial GRb immunostaining ( figure 2C, p¼0.18, KruskaleWallis) . Figure 2B shows representative sections from each of the participant groups. Among the 10 patients with mRNA above the limit of detection and matched immunohistochemistry samples, there was no correlation between mRNA levels and epithelial expression of GRb (data not shown).
Glucocorticoid receptor a (GRa) immunostaining was diffusely present in the epithelium and submucosa with no difference between participant subgroups (data not shown), but GRa immunostaining was more abundant than GRb immunostaining in all groups.
HDAC1 and HDAC2 immunostaining was also more prominent in the epithelium, with occasional submucosal cells. There was no difference between subgroups (figure 3AeC; HDAC1, p¼0.55, KruskaleWallis and HDAC2, p¼0.89, KruskaleWallis). In the SA group, there was no significant difference in mRNA or protein expression for HDAC1 and HDAC2 between those taking theophyllines and those who were not (data not shown).
Western blot analysis and immunocytochemical analysis of PBEC lysates
Immunocytochemical analysis of cultured PBECs revealed predominantly cytoplasmic location of GRb with some cells demonstrating concomitant nuclear expression (figure 4A). In view of the 'dissociation' between mRNA levels of GRb and immunohistochemical staining, further analysis of GRbantibody specificity was performed using western blots of cultured PBECS. This consistently demonstrated two bands (figure 4B); one band was identified at the anticipated molecular weight of GRb at 90 kDa but a second higher molecular weight band (w180 kDa, band 2) was consistently present on the PBEC blots and always stronger than the GRb band in both nuclear and cytoplasmic compartments ( figure 5, online supplement) .
To evaluate the 180 kDa band, immunoprecipitation using both GRb antibodies was performed using BEAS-2B cells (where the 180 kDa band was also identified) and PBEC lysates. The higher molecular weight bands were cut out of the gel and sequenced. In both BEAS-2B cells and PBECs, this identified heavy chain clathrin as the 180 kDa protein.
To further confirm that clathrin was responsible for band 2, recombinant clathrin was run on a gel and probed separately with anti-GRb and anti-clathrin antibodies ( figure 4C ). Both antibodies identified the clathrin protein, confirming this band was clathrin and importantly both anti-GRb antibodies displayed similar bands on western blotting. There was no significant difference in clathrin mRNA expression in bronchial biopsies between groups (figure 4D).
DISCUSSION
This study examined GRb, HDAC1 and HDAC2 gene expression and protein in the largest cohort of patients with severe asthma to date. We demonstrated low levels of GRb mRNA expression in bronchial biopsies from a minority of patients with severe asthma despite prominent immunostaining in matched tissue sections. GRb is upregulated at the transcriptional level by steroid exposure in an airway epithelial cell line 22 and of the 13 participants in the present study in whom GRb mRNA was detectable, 11 were on inhaled steroids; however, in the majority of patients with asthma on steroid therapy, GRb was not detectable. No previous study has reported the existence of a 180 kDa band on western blot with commercially available GRb antibodies, which we have subsequently identified as heavy chain clathrin. Therefore it is impossible to comment with confidence on the distribution of GRb using these antibodies. Previous data suggested predominantly nuclear expression of GRb, though cytoplasmic expression has been reported. 23 Clathrin is a ubiquitous protein complex involved in transport vesicle formation to mediate endocytosis of transmembrane receptors, 24 and given the low GRb mRNA expression in a few patients, we believe that cross-reactivity with clathrin resulted in prominent biopsy staining. The only other bronchial biopsy study in severe asthma reported significant upregulation of GRb in bronchial biopsies from patients with severe asthma. 15 Their pattern of staining was similar to that reported here but tissue expression of GRb at the mRNA level was not examined. Other studies examining GRb expression in severe asthma using these antibodies have reported variable associations. GRb immunoreactivity was increased in PBMCs and bronchoalveolar lavage (BAL) cells from patients with severe asthma. 3 12 25 However, another PBMC study was unable to identify any GRb immunoreactivity in healthy volunteers and patients with asthma that is steroid sensitive or resistant. 16 Of note, that study was unable to identify GRb mRNA in the first round of PCR, though it did on the second cycle of nested PCR. 16 A further PBMC study by Torrego et al reported 600-fold lower GRb mRNA expression than GRa, but that group was also unable to detect any GRb expression on western blot. 17 Goleva et al demonstrated readily appreciable GRb expression using immunohistochemistry in BAL macrophages but demonstrated only femtograms of GRb mRNA. 12 In other inflammatory disease states, such as glaucoma, ulcerative colitis and rheumatoid arthritis, GRb expression has been reported to be upregulated in glucocorticoid-unresponsive disease, although again there is controversy.
26e30 Some of these studies have looked at mRNA expression from PBMCs rather than immunohistochemistry. For example, GRb mRNA was detectable in PBMCs from patients with glucocorticoid-resistant ulcerative colitis compared with low detection in glucocorticoidresponsive disease and healthy volunteers. 27 This same group also demonstrated elevated PBMC GRb mRNA in patients with active ulcerative colitis compared with inactive disease or Crohn's disease, though this was disputed by Hausmann et al, who did not find elevated PBMC GRb mRNA in relation to steroid resistance. 26 29 PBMC GRb mRNA and GRb-positive PBMCs were increased in steroid-resistant rheumatoid arthritis. 28 Zhang et al were able to confirm that glaucomatous trabecular meshwork cells expressed lower levels of GRb protein by western blotting and these cells were more sensitive to the effects of steroids compared with normal trabecular meshwork cells. 30 A recent immunohistochemistry study by Ishida et al reported increased GRb expression in patients with severe allergic rhinitis compared with healthy controls, and of note, GRb mRNA was not assessed in this study. 31 Our data suggest that tissue immunohistochemistry with these GRb antibodies is unreliable due to concomitant clathrin staining. This illustrates the problems associated with using antibodies for immunohistochemistry in the absence of validation with other methods, for example, mRNA expression and target protein specificity using western blots. If multiple bands are seen on western blot from the target tissue, we would suggest that this antibody may be inappropriate for use in immunofluorescence, immunocytochemistry or immunohistochemistry. These techniques have been widely used in the GRb literature and this study questions the validity of previous immunohistochemical and immunocytochemical data utilising these antibodies and supports the need for western blotting techniques. In view of the low mRNA signal compared with that for GRa, we would further conclude that GRb is not highly expressed in the airways of patients with severe asthma. Given the substantially higher expression of GRa, GRb is unlikely to function as a dominant-negative isoform of GRa and this mechanism has little to do with the relative steroid resistance seen in this group.
Another proposed mechanism for the induction of steroid resistance by GRb is reduced tissue expression of HDAC2 mRNA and recent data suggested reduced HDAC2 in severe asthma may be regulated by GRb overexpression. If this mechanism of HDAC2 regulation is correct, then our data provide no support that it is relevant in severe asthma because, consistent with the low levels of GRb expression in severe asthma biopsies, we identified no reduction in HDAC2 expression in matched biopsies from the same patients when compared with normal controls and patients with mild to moderate asthma. Reduced HDAC2 tissue expression has been described in patients with chronic obstructive pulmonary disease (COPD) and those who smoke and is associated with reduced HDAC function, 32 33 but the data in asthmatic airway samples are conflicting. One study suggested decreased expression of HDAC1 and HDAC2 in mild asthma which increased with steroid treatment. 34 In more severe asthma, Bergeron et al reported similar HDAC2 expression between patients with asthma that is steroid resistant and steroid responsive, 15 whereas another study reported reduced HDAC2 mRNA expression in BAL cells. 10 Importantly, in previous studies in which HDAC mRNA data have been presented along with functional HDAC activity, when there has been a reduction in HDAC activity, there has been a concomitant reduction in HDAC mRNA. 34 Thus, there has been no suggestion that reduced HDAC function in asthma or COPD disease is due to any specific alteration in HDAC function, but rather reduced activity is due to reduced tissue expression. Therefore, we believe it is reasonable to conclude that an absence of reduction of HDAC1 and HDAC2 in this large cohort of patient with refractory asthma argues against this being the mechanism of steroid resistance in this patient group.
At a transcriptional level, we found HDAC1 was increased in patients with severe asthma on higher dose steroid treatment compared with healthy volunteers but not those with mild to moderate asthma, which is consistent with the previously described steroid effect of upregulating HDAC1. 35 However, this difference appeared small compared with milder disease and no difference was identified in HDAC1 protein expression. Thus, even if HDAC1 is upregulated by steroid treatment, the fact that many patients with severe asthma remain dependent on oral steroids suggests that this upregulation does not enhance steroid efficacy in this group. There was no association between HDAC2 and theophylline treatment, suggesting that the normal HDAC2 levels in severe asthma are not due to theophylline treatment, as has previously been suggested. 36 37 The close correlation of HDAC2 with GRa expression at the transcriptional level suggests that these molecules are co-regulated, with increased expression of both molecules tending to increase steroid responsiveness. We did not specifically examine bronchoalveolar macrophages in the present study and thus a reduction in HDAC2 activity in macrophages contributing to steroid resistance cannot be completely excluded. However, other important and relevant immunological mechanisms in asthma pathogenesis have been identified in proximal airway samples obtained at bronchoscopy.
In conclusion, we have demonstrated that commercially available GRb antibodies cross-react with clathrin and are unreliable for the analysis of GRb expression in situ. GRb mRNA was expressed at low levels in the airways with no difference between steroid-sensitive and severe disease. Our findings may explain the discrepant reports for the role of GRb in steroidresistant states in a variety of diseases, and do not support the view that GRb plays a role in severe asthma. In addition, our data suggest that downregulation of HDAC1 or HDAC2 does not occur in severe asthma, and so the mechanism of relative steroid resistance in severe asthma remains unclear.
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